Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,101 to 3,120 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Folic Acid and Zinc Supplementation vs Placebo: serious adverse events | 7 of 1,185 5 of 1,185 | 0.2 points -0.5 to 0.8 | 2,370 | NCT01857310 Folic Acid and Zinc Supplementation Trial (FAZST) |
| Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide | 14 of 224 111 of 2,146 | 1.1 points -1.6 to 5.1 | 2,370 | NCT01919697 Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) |
| Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) | 123 of 224 620 of 2,146 | 26.0 points 19.2 to 32.7 | 2,370 | NCT01919697 Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) |
| Plecanatide 3 mg vs Plecantide 6 mg: Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline | 192 of 224 1,498 of 2,146 | 15.9 points 10.4 to 20.4 | 2,370 | NCT01919697 Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) |
| Plecanatide 3 mg vs Plecanatide 6 mg: deaths from any cause | 0 of 224 1 of 2,146 | -0.0 points -0.3 to 1.6 | 2,370 | NCT01919697 Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) |
| Plecanatide 3 mg vs Plecanatide 6 mg: serious adverse events | 8 of 224 32 of 2,146 | 2.1 points 0.2 to 5.4 | 2,370 | NCT01919697 Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) |
| Intervention vs Usual Care: Medically Treated Falls | 328 of 1,106 349 of 1,261 | 2.0 points -1.7 to 5.6 | 2,367 | NCT05689554 Reducing CNS-Active Medications to Prevent Falls and Injuries in Older Adults |
| Intervention vs Usual Care: deaths from any cause | 86 of 1,106 72 of 1,261 | 2.1 points 0.0 to 4.1 | 2,367 | NCT05689554 Reducing CNS-Active Medications to Prevent Falls and Injuries in Older Adults |
| Intervention vs Usual Care: serious adverse events | 10 of 1,106 4 of 1,261 | 0.6 points -0.1 to 1.4 | 2,367 | NCT05689554 Reducing CNS-Active Medications to Prevent Falls and Injuries in Older Adults |
| Information vs Usual Care: deaths from any cause | 39 of 1,198 35 of 1,166 | 0.3 points -1.2 to 1.7 | 2,364 | NCT04852055 Effect of an Advance Care Planning Intervention |
| Transdisciplinary Approach vs Multidisciplinary Approach: Depressive Symptoms | 37 of 680 90 of 1,676 | 0.1 points -1.8 to 2.3 | 2,356 | NCT03442322 Optimizing Care for Patients With Dementia |
| BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: Time to First Severe Asthma Exacerbation, While on Treatment Strategy (Participants Aged >=18 Years) | 71 of 1,180 126 of 1,173 | -4.7 points -7.0 to -2.5 | 2,353 | NCT05505734 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma |
| BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: Time to First Severe Asthma Exacerbation, Treatment Policy Strategy (Participants Aged >=18 Years) | 73 of 1,180 131 of 1,173 | -5.0 points -7.3 to -2.7 | 2,353 | NCT05505734 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma |
| Folic Acid 4 mg vs Placebo: Spontaneous Abortion | 27 of 1,172 21 of 1,180 | 0.5 points -0.6 to 1.7 | 2,352 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Roflumilast vs Placebo: serious adverse events | 180 of 1,178 162 of 1,174 | 1.5 points -1.4 to 4.3 | 2,352 | NCT01443845 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) |
| Folic Acid 4 mg vs Placebo: Premature Rupture of Membranes | 215 of 1,169 224 of 1,180 | -0.6 points -3.7 to 2.6 | 2,349 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Placenta Abruption | 12 of 1,169 19 of 1,179 | -0.6 points -1.6 to 0.4 | 2,348 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Comparator: ENGERIX-B Hep B Vaccination vs Pooled Sci-B-Vac®: Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2) | 561 of 592 1,740 of 1,753 | -4.5 points -6.6 to -2.9 | 2,345 | NCT03408730 Lot-to-lot Consistency of Sci-B-Vac™ in Adults |
| Referred Subjects vs Not Referred Subjects: Percentage of Post-Acute MI Patients Who Are Referred for Sudden Cardiac Death Risk Stratification > Risk (SCD) Stratification and Management | 236 of 1,170 934 of 1,170 | -59.7 points -62.8 to -56.3 | 2,340 | NCT03715790 Improve SCA Bridge Study |
| Self-collected Specimens vs Physician-sampled Specimens: Percentage of a Valid Specimen, According to the Presence of the Beta-globin Gene in Specimens | 1,170 of 1,170 1,170 of 1,170 | 0.0 points -0.3 to 0.3 | 2,340 | NCT04472377 HPV Typing Between Self- and Physician-sampled |
Code
curl "https://conductscience.org/api/comparisons/v1?page=156"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=156
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01857310-sae",
"title": "Folic Acid and Zinc Supplementation vs Placebo: serious adverse events",
"summary": "7 of 1185 against 5 of 1185; risk difference 0.2 points, 95% interval -0.5 to 0.8; NCT01857310, Folic Acid and Zinc Supplementation Trial (FAZST)",
"record": "/library/comparisons/NCT01857310-sae",
"nct_id": "NCT01857310",
"kind": "serious-adverse-events",
"participants": 2370,
"risk_difference": {
"value": 0.0016877637130801688,
"lower": -0.0047029480422807095,
"upper": 0.008375283293623425
},
"group_1": "7 of 1,185",
"group_2": "5 of 1,185",
"difference": "0.2 points",
"interval": "-0.5 to 0.8",
"trial_title": "Folic Acid and Zinc Supplementation Trial (FAZST)"
},
{
"id": "NCT01919697-0a6e7756",
"title": "Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide",
"summary": "14 of 224 against 111 of 2146; risk difference 1.1 points, 95% interval -1.6 to 5.1; NCT01919697, Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)",
"record": "/library/comparisons/NCT01919697-0a6e7756",
"nct_id": "NCT01919697",
"kind": "outcome",
"participants": 2370,
"risk_difference": {
"value": 0.010775862068965518,
"lower": -0.01613908643881387,
"upper": 0.05135773247189961
},
"group_1": "14 of 224",
"group_2": "111 of 2,146",
"difference": "1.1 points",
"interval": "-1.6 to 5.1",
"trial_title": "Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=157",
"request_id": "aYhxdggrhW2rPNIY"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant